文献速递妇科产科

肥胖合并非典型增生或低级别子宫内膜癌患者医学监督下术前减重项目的可行性

The feasibility of a medically supervised preoperative weight loss program in patients with obesity and atypical hyperplasia, or low-grade endometrial carcinoma.
PubMed 文献 · Gynecol Oncol · 2026-08-04

前瞻性队列研究纳入104例BMI≥40 kg/m²的非典型增生或低级别子宫内膜癌患者,接受12周医学监督下Optifast 900®全代餐或混合方案术前减重,72例完成干预,从咨询至手术平均体重变化为-15.0 kg(SD 10.2,p<0.01),结论认为术前减重可行且与短期显著体重下降相关。

要点

  • 医学监督下12周全代餐或混合方案术前减重,69.2%患者完成干预。
  • 完成者从咨询至手术平均减重15.0 kg,短期减重效果显著。
  • 术后8周体重变化-0.7 kg,术后12个月体重变化+3.53 kg。

核心结论

  • 在选定的肥胖合并非典型增生或低风险子宫内膜癌患者中,术前减重看似可行且与短期显著体重下降相关。
  • 需要更大规模的比较研究来确定围手术期获益和肿瘤学安全性。

研究设计与样本

  • 前瞻性队列研究,纳入BMI≥40 kg/m²的非典型增生或子宫内膜癌患者,术前接受医学监督下Optifast 900®全代餐12周或混合方案减重,术后随访12个月。

主要发现

  • 从咨询至手术的平均体重变化为-15.0 kg(SD 10.2,p<0.01)。
  • 最终病理(FIGO 2009):68/72例为非典型增生或I期子宫内膜癌,3例为II期,1例为IIIC1期。
  • 从手术至术后8周的平均体重变化为-0.7 kg(SD 6.5,p=0.4280),从手术至术后12个月的平均体重变化为+3.53 kg(SD 10.5,p=0.215)。
  • 发生1例复发并于2年时死亡(IA期、1级子宫内膜癌、MMRd)。

临床怎么用

  • 对于肥胖合并非典型增生或低级别子宫内膜癌患者,可考虑在医学监督下实施术前减重项目。
  • 术前减重可能实现显著短期体重下降,但围手术期获益和肿瘤学安全性尚需更大规模比较研究验证。

局限性

  • 本研究为单臂前瞻性队列研究,二次分析为探索性。
  • 研究仅纳入BMI≥40 kg/m²的选定患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the efficacy of preoperative weight loss in women with obesity and either atypical hyperplasia (AEH), or low grade endometrial carcinoma (EC), measured through weight change. METHODS: Prospective cohort study in women with AEH or EC, and a BMI of ≥ 40 kg/m2. Preoperative weight loss was medically supervised, utilizing Optifast 900® full meal replacement for 12 weeks, or a hybrid approach. Follow up was 12 months after surgery. Demographic, laboratory, pathologic, clinical, and follow up outcomes were collected. Continuous variables were summarized as mean (SD) or median [IQR] based on normality (Shapiro-Wilk test); categorical variables as frequencies and percentages. Changes in weight and BMI were analyzed using paired t-tests or Wilcoxon Signed-Rank tests accordingly. Secondary analyses were exploratory. Patient experience was explored utilizing qualitative interviews and analyzed with thematic analysis until saturation. RESULT: 104 patients enrolled from November 2020 to January 2022. Mean age 56 (SD 10.9), and BMI 50.0 kg/m2 (SD 7.9). 72/104 (69.2%) completed the intervention, and mean weight difference from consultation to surgery was -15.0 kg (SD 10.2, p < 0.01). Final pathology (FIGO 2009): 68/72 AEH or stage I EC, 3 stage II, 1 stage IIIC1. Mean weight difference from surgery to 8 weeks was -0.7 kg (SD 6.5, p 0.4280), and from surgery to 12 months was +3.53 kg (SD 10.5, p = 0.215). There was 1 recurrence that led to death at 2 years (stage IA, grade 1 EC, MMRd). CONCLUSION: Preoperative weight loss appeared feasible and was associated with substantial short-term weight loss in selected patients with obesity and low risk endometrial cancer or AEH. Larger comparative studies are needed to determine perioperative benefit and oncologic safety.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Aubrey C, Svajger B, Batara J, et al. The feasibility of a medically supervised preoperative weight loss program in patients with obesity and atypical hyperplasia, or low-grade endometrial carcinoma. Gynecol Oncol. 2026. PMID: 42551137. doi:10.1016/j.ygyno.2026.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。